Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Cardiology

The Long View: Lifelong Monitoring and Family Care

At a Glance

Naxos disease requires lifelong heart monitoring because abnormal rhythms and heart-muscle changes can appear with age. Siblings should receive cascade screening with JUP genetic testing and a cardiology evaluation, while people with two mutated copies may need to restrict high-intensity exercise.

Because Naxos disease is a progressive condition, receiving a diagnosis is not a one-time event—it is the start of a lifelong partnership with your medical team. The goal of long-term monitoring is to stay “one step ahead” of the disease, ensuring that any changes in heart rhythm or muscle function are caught and managed early [1][2].

The Lifelong Monitoring Protocol

Even if you or your child feel perfectly healthy, regular “check-ups” for the heart are essential. These tests allow doctors to monitor the phenotype—the physical way the disease is showing up in the body—which can change as a person gets older [3][4].

Standard surveillance typically includes the following tests on an individualized, age- and risk-dependent schedule, though your doctor may recommend more frequent visits during the high-risk teenage years [2][5]:

  • 12-Lead ECG: A quick look at the heart’s electrical activity at rest.
  • 24-Hour Holter Monitor: A portable device that records every heartbeat for a full day, helping to catch extra beats or rhythm “hiccups” that a standard ECG might miss [6].
  • Echocardiogram: An ultrasound used to check the size and pumping strength of the heart’s chambers [7].
  • Cardiac MRI: The most detailed imaging tool available, used to check for signs of fibrous scar tissue, though doctors must weigh the need for detailed information against the burden of sedation and repeated gadolinium contrast exposure, especially in children [8][7].

Family Screening: The Cascade Effect

Naxos disease is autosomal recessive, meaning it occurs when a child inherits a mutated gene from both parents. Because of this, siblings of a person with Naxos disease have a 25% chance of also being affected (inheriting two mutated copies), a 50% chance of being a carrier (inheriting one mutated copy), and a 25% chance of inheriting neither [9].

Doctors use a process called cascade screening to evaluate the family [10]:

  1. Genetic Testing: Siblings should be tested for the specific JUP gene mutations identified in the first family member diagnosed [3][11].
  2. Clinical Evaluation: Even if a sibling does not have the “woolly hair” or skin signs, they should still have a baseline heart evaluation by a cardiologist [12].

Genotype-Positive, Phenotype-Negative

It is crucial not to confuse having one variant (being a carrier) with having the disease. Sometimes, a family member will test “positive” for biallelic mutations (two mutated copies, or genotype-positive) but have a completely normal heart on all scans (phenotype-negative). While this is good news, it does not mean they are “cleared” [13].

In Naxos disease, heart issues are age-dependent, meaning they can appear later in life even if early tests are normal [3]. For this reason, these family members must:

  • Continue regular cardiac monitoring as prescribed by their team [14].
  • Restrict high-intensity exercise, as heavy exertion can act as a “trigger” that causes the disease to show up earlier or more severely [15][16].

Managing “Scan Anxiety”

Living with a condition that requires constant monitoring can take a psychological toll, often referred to as scan anxiety. It is normal to feel a sense of dread or heightened stress in the weeks leading up to a cardiology appointment [17].

To help manage this:

  • Focus on the Goal: Remind yourself that these scans are a tool for protection, not just a search for “bad news.”
  • Build a Routine: Having a consistent plan for scan days (like a favorite family meal afterward) can help normalize the process.
  • Seek Support: Many families find it helpful to speak with a genetic counselor or a mental health professional who specializes in chronic illness to navigate the uncertainty of genetic results [10][18].

Common questions in this guide

What heart tests are used to monitor Naxos disease over time?
Follow-up may include a 12-lead ECG, a 24-hour Holter monitor, an echocardiogram, and sometimes cardiac MRI. The schedule is tailored to age and risk, with closer follow-up often considered during the teenage years.
Should brothers and sisters of someone with Naxos disease be tested?
Yes. Cascade screening usually includes testing for the family's known JUP gene changes and a baseline heart evaluation by a cardiologist, even if a sibling has no woolly hair or skin findings.
What does it mean if someone has two JUP changes but a normal heart scan?
This is called being genotype-positive and phenotype-negative: the person has two disease-associated gene changes but no detectable heart findings yet. Because heart involvement can develop later, regular cardiac monitoring should continue and the care team may recommend limiting high-intensity exercise.
What are the chances that a sibling will have Naxos disease or carry it?
When both parents carry a disease-causing gene change, each child has a 25% chance of having Naxos disease, a 50% chance of being a carrier with one changed copy, and a 25% chance of inheriting neither changed copy. These probabilities apply separately to each pregnancy.
How can families cope with anxiety before repeated heart scans?
Scan anxiety is common when appointments and results feel uncertain. A consistent scan-day routine, focusing on the protective purpose of monitoring, and support from a genetic counselor or mental health professional may make the process easier.
Does a Naxos disease carrier need the same activity restrictions as someone with the disease?
A person with one changed copy is a carrier and does not have the same genetic status as someone with two changed copies. Activity guidance should be individualized by the cardiology and genetics team; people with biallelic disease may be advised to avoid high-intensity exercise.

Get notified when new evidence is published on Naxos disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy.

    Towbin JA, McKenna WJ, Abrams DJ, et al.

    Heart rhythm 2019; (16(11)):e301-e372 doi:10.1016/j.hrthm.2019.05.007.

    PMID: 31078652
  2. 2

    Arrhythmogenic Right Ventricular Cardiomyopathy Prevalence and Arrhythmic Outcomes in At-Risk Family Members: A Systematic Review and Meta-Analysis.

    Sharma A, Bosman LP, Tichnell C, et al.

    Circulation. Genomic and precision medicine 2022; (15(3)):e003530 doi:10.1161/CIRCGEN.121.003530.

    PMID: 35579515
  3. 3

    Arrhythmogenic right ventricular cardiomyopathy in patients with biallelic JUP-associated skin fragility.

    Vahidnezhad H, Youssefian L, Faghankhani M, et al.

    Scientific reports 2020; (10(1)):21622 doi:10.1038/s41598-020-78344-9.

    PMID: 33303784
  4. 4

    Naxos disease - a narrative review.

    Leopoulou M, Mattsson G, LeQuang JA, et al.

    Expert review of cardiovascular therapy 2020; (18(11)):801-808 doi:10.1080/14779072.2020.1828064.

    PMID: 32966140
  5. 5

    Arrhythmic risk assessment in genotyped families with arrhythmogenic right ventricular cardiomyopathy.

    Protonotarios A, Anastasakis A, Panagiotakos DB, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2016; (18(4)):610-6 doi:10.1093/europace/euv061.

    PMID: 25825460
  6. 6

    Family Screening in Relatives at Risk for Plakophilin-2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy.

    Muller SA, Asatryan B, Gasperetti A, et al.

    Circulation 2025; (152(5)):313-326 doi:10.1161/CIRCULATIONAHA.125.074058.

    PMID: 40525281
  7. 7

    Imaging Naxos disease and related cardiocutaneous syndromes: the NAXCARE multimodality approach.

    Protonotarios I, Alsergani H, Anastasakis A, et al.

    Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2026; doi:10.1016/j.hjc.2026.03.007.

    PMID: 41936932
  8. 8

    Evolving Diagnostic Criteria for Arrhythmogenic Cardiomyopathy.

    Corrado D, Zorzi A, Cipriani A, et al.

    Journal of the American Heart Association 2021; (10(18)):e021987 doi:10.1161/JAHA.121.021987.

    PMID: 34533054
  9. 9

    Arrhythmogenic Right Ventricular Cardiomyopathy in Pediatric Patients: An Important but Underrecognized Clinical Entity.

    Te Riele ASJM, James CA, Calkins H, Tsatsopoulou A

    Frontiers in pediatrics 2021; (9()):750916 doi:10.3389/fped.2021.750916.

    PMID: 34926342
  10. 10

    [Genetic diagnostics for cardiomyopathies].

    Czepluch F, Wollnik B, Hasenfuß G

    Deutsche medizinische Wochenschrift (1946) 2017; (142(9)):657-664 doi:10.1055/s-0042-112183.

    PMID: 28454199
  11. 11

    Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo.

    van Lint FHM, Murray B, Tichnell C, et al.

    Circulation. Genomic and precision medicine 2019; (12(8)):e002467 doi:10.1161/CIRCGEN.119.002467.

    PMID: 31386562
  12. 12

    Naxos disease: current insights from early clinical observations to genetics and precision medicine.

    Xylouri Z, Al-Sergani H, Protonotarios I, et al.

    Internal and emergency medicine 2026; doi:10.1007/s11739-026-04559-9.

    PMID: 42932075
  13. 13

    Sport and exercise in genotype positive (+) phenotype negative (-) individuals: current dilemmas and future perspectives.

    Paldino A, Rossi M, Dal Ferro M, et al.

    European journal of preventive cardiology 2023; (30(9)):871-883 doi:10.1093/eurjpc/zwad079.

    PMID: 36929832
  14. 14

    Arrhythmogenic right ventricular cardiomyopathy in the pediatric population.

    Cohen MI, Atkins MB

    Current opinion in cardiology 2022; (37(1)):99-108 doi:10.1097/HCO.0000000000000937.

    PMID: 34857718
  15. 15

    Exercise restriction is protective for genotype-positive family members of arrhythmogenic right ventricular cardiomyopathy patients.

    Wang W, Tichnell C, Murray BA, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2020; (22(8)):1270-1278 doi:10.1093/europace/euaa105.

    PMID: 32572458
  16. 16

    Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers.

    Sawant AC, Te Riele AS, Tichnell C, et al.

    Heart rhythm 2016; (13(1)):199-207.

    PMID: 26321091
  17. 17

    Arrhythmias as Presentation of Genetic Cardiomyopathy.

    Lukas Laws J, Lancaster MC, Ben Shoemaker M, et al.

    Circulation research 2022; (130(11)):1698-1722 doi:10.1161/CIRCRESAHA.122.319835.

    PMID: 35617362
  18. 18

    Perceptions of genetic variant reclassification in patients with inherited cardiac disease.

    Wong EK, Bartels K, Hathaway J, et al.

    European journal of human genetics : EJHG 2019; (27(7)):1134-1142 doi:10.1038/s41431-019-0377-6.

    PMID: 30903112

This page is for informational purposes only and does not replace medical advice. A cardiologist and genetic counselor should tailor Naxos disease testing, exercise guidance, and follow-up to your family.